NovellusDx Tissue Collection Protocol
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.
Patients That Have Been Diagnosed With Colorectal Cancer|Patients Eligible for Tumor Biopsy
Correct identification of tumor mutant genes, Correct identification of tumor mutant genes, in over 85% of the cases, up to 12 month
NovellusDx is developing a diagnostic platform for the personalized cancer therapy based on patient derived tumor tissue. The assay is able to sense activating mutations by monitoring their effect on a chip-based device.